#124 A phase II, multicentre, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer | International Journal of Gynecologic Cancer

Subscribe
Log In More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
Basket
Search More

Search for this keyword

Advanced search

Close More
Main menu

Latest content

Current issue

Archive

Authors

About

YouTube

Podcasts

Zoom Journal Club
Subscribe
Log in More

Log in via Institution
Log in via OpenAthens
Log in via your Society

Log in using your username and password
For personal accounts OR managers of institutional accounts

Username *

Password *

Forgot your log in details?Register a new account?
Forgot your user name or password?
BMJ Journals

Article metrics

Poster/ePoster Sessions

15. Trial In Progress

#124 A phase II, multicentre, open-label study of abemaciclib and letrozole in patients with estrogen receptor-positive rare ovarian cancer

Free

Online download statistics by month:

Online download statistics by month: September 2023 to October 2024

	Abstract	Full	Pdf
Sep 2023	30	0	3
Oct 2023	115	0	12
Nov 2023	97	0	8
Dec 2023	41	0	5
Jan 2024	19	0	0
Feb 2024	51	0	6
Mar 2024	69	0	23
Apr 2024	40	0	5
May 2024	49	0	3
Jun 2024	32	0	3
Jul 2024	23	0	7
Aug 2024	20	0	7
Sep 2024	33	0	6
Oct 2024	4	0	0
Total	623	0	88